Human immunodeficiency virus (HIV)-related neuropathic pain is a debilitating chronic condition that is severe and unrelenting. Despite extensive research, the detailed neuropathological mechanisms remain unknown, which hinders our ability to develop effective treatments. In this study, we investigated the role of proinflammatory molecules, tumor necrosis factor-a (TNFa), CXCR4 and stromal-derived factor-1 a (SDF1a), in the L4/5 dorsal root ganglia (DRG) and the spinal dorsal horn in HIV gp120 protein-mediated neuropathic pain. Our results showed that the application of HIV gp120 to the sciatic nerve induced upregulation of TNFa, CXCR4 and SDF1a in both the DRG and the lumbar spinal dorsal horn. Non-replicating herpes simplex virus (HSV) vector encoding the p55TNFSR gene and producing a TNF-soluble receptor (TNFSR) to block bioactivity of TNFa reversed mechanical allodynia. Intrathecal AMD3100 (CXCR4 antagonist) increased mechanical threshold. The HSV vectors expressing p55TNFSR reversed upregulation of TNFa, CXCR4 and SDF1a induced by gp120 in the DRG and the spinal dorsal horn. These studies suggest that proinflammatory TNFa to the CXCR4/SDF1 pathway has an important role in the HIV-related neuropathic pain state and that blocking the proinflammatory cytokines or chemokines is able to reduce neuropathic pain. This work provides a novel gene therapy proof-of-concept for HIV-associated neuropathic pain.
INTRODUCTION
Peripheral neuropathy presents clinically in 30-60% of people living with human immunodeficiency virus (HIV), and nearly all AIDS patients have an evidence of peripheral neuropathy at autopsy. 1 HIV-associated sensory neuropathy (HIV-SN) is one of the most common forms of peripheral neuropathy. 2, 3 It has been found that 57% of HIV-infected individuals have distal symmetrical SN and 38% have neuropathic pain. 4 Pain is one of the most common complaint of HIV-SN; patients often have tactile allodynia in a stocking and/or glove distribution. 5 HIV-related neuropathic pain is a debilitating chronic condition that is severe and unrelenting. Despite extensive research, the neuropathological mechanisms responsible for the development of this devastating condition remain largely unknown (see reviews Kamerman et al. 6 and Hao 7 )
. HIV viral components (for example, coat protein gp120) are thought to exert toxic actions on the dorsal root ganglia (DRG) sensory neurons and the spinal cord. 8, 9 A direct role of gp120 on the sciatic nerve in the genesis of HIV-SN has been suggested. [10] [11] [12] [13] Established animal models of HIV-related neuropathic pain may, in part, imitate clinical characteristics and provide new avenues for basic research and therapeutic development. 10, 12, 14 The application of recombinant HIV gp120 to the rat sciatic nerve produces mechanical allodynia. 10, 12 This pain behavior is associated with inflammatory activation in the DRG and the spinal cord. 10, 13, 15 Proinflammatory cytokines (for example, tumor necrosis factor-a (TNFa)) have an important role in the development and maintenance of inflammatory and neuropathic pain in preclinical studies. [16] [17] [18] [19] [20] Along with others, we have reported that the application of the recombinant gp120 to the sciatic nerve increases TNFa expression in the DRG and the spinal cord. 10, 15 It is possible that CXCR4 acts as an important inflammatory factor in the neuropathogenesis of HIV/AIDS. 21, 22 CXCR4 is required for gp120-induced cell death in human neuroblastoma cells. 23 Furthermore, CXCR4 inhibitor reverses tactile allodynia induced by antiretroviral toxicity. 24 The mRNA expression of chemokine stromal-derived factor-1 (SDF1, ligand of CXCR4) in the sensory neurons is upregulated in a tactile hyperalgesia rats following chronic morphine treatment. 25 Previous studies have shown that TNFa, CXCR4 and SDF1a are involved in neuropathic pain induced by nerve injury or antiretroviral toxicity. 24, 26 Importantly, CXCR4 expression is inhibited significantly by TNFa antibody in cultured HGC27 cells. 27 However, it is not clear if TNFa to the CXCR4/SDF1a pathway is involved in the neuropathic pain state induced by gp120.
We have constructed the highly replication-defective herpes simplex virus (HSV) genomic vectors that establish a persistent state that can be used to deliver and express transgenes in the DRG neurons. Transduction of the DRG sensory neurons by footpad inoculation with the HSV-based vectors encoding human preproenkephalin gene produces an antihyperalgesic effect in models of acute thermal pain 28 and inflammatory pain. 29, 30 The DRG neurons transduced with the HSV vector transport transgene-coded enkephalin centrally in the bipolar axon of the primary sensory afferents. 31 These HSV vectors encoding preproenkephalin induce physiological improvement in visceral pain induced by bladder irritation. 32 It is known that TNF-soluble receptor (TNFSR) blocks the bioactivity of TNFa. Recently, we have demonstrated that the HSVbased vectors can be used to transduce neurons of the DRG to release TNFSR from nerve terminals in the spinal cord to produce antinociceptive effects in models of neuropathic pain and morphine tolerance. [33] [34] [35] [36] HIV neuropathic pain with a sizeable morbidity is difficult to manage. 4 The HSV vector-mediated gene transfer may provide a novel approach to treating neuropathic pain. 37 In this study, we hypothesized that gp120 upregulates TNFa in the DRG and the spinal dorsal horn, which in turn upregulates the CXCR4/SDF1 pathway. We found that the HSV vector-mediated TNFSR expression produced antinociceptive effects on neuropathic pain induced by the gp120 application to the sciatic nerve and reduced proinflammatory molecules TNFa and CXCR4/SDF1 in the DRG and the spinal dorsal horn.
RESULTS
The peripheral gp120 induced the expression of TNFa, CXCR4 and SDF1a in the DRG and the spinal cord There is an increase in TNFa in the spinal cord in 'pain-positive' HIV patients. 8 CXCR4 and its ligand SDF1a are important inflammatory factors in the neuropathogenesis of HIV/AIDS. 21 In this study, we tested if neuropathic pain induced by HIV gp120 affected TNFa, CXCR4 and SDF1a expression in the DRG and the spinal dorsal horn. To induce HIV neuropathic pain, rats received a recombinant gp120 application to the sciatic nerve 10, 15 (for details, see Materials and methods section). In the sham group, rats received an identical surgery except gp120. We harvested the ipsilateral L4/5 DRG and the spinal cord 2 or 7 weeks post gp120 application. The pooled L4/5 DRG and the spinal dorsal horn were used to test neurochemical changes. Using western blots, we found that the application of gp120 to the sciatic nerve significantly increased the expression of TNFa (Po0.01 vs sham, Figure 1a The effect of the HSV vectors expressing p55TNFSR on mechanical allodynia induced by HIV gp120 TNFSR may prevent TNFa from binding to its receptor on the plasma membranes of cells to reduce the bioactivity of TNFa. We have demonstrated that intrathecal administration of recombinant p55TNFSR reversed mechanical allodynia induced by gp120. 15 In this study, we examined whether overexpression of p55TNFSR mediated by the HSV vectors (T0TNFSR) reduced HIV neuropathic pain induced by gp120. Mechanical threshold was measured by the von Frey test 38 and then determined using the up-down method 38, 39 (see the detailed description in Materials and Methods section). One-week post gp120 application, rats exhibited mechanical allodynia manifested as a reduced paw mechanical threshold. Next, 30 ml T0TNFSR or T0Z (1 Â 10 9 plaque-forming unit (PFU) ml -1 ) was injected (blindly to observers) into the plantar surface of the hind foot ipsilateral to the gp120 application. To determine whether there were significant differences of timecourse curves between experimental groups two-way analysis of variance (ANOVA) with one within-subjects factor (time) and one between-subjects factor (groups) of a general linear model with repeated-measures analysis (SPSS software, Armonk, NY, USA) was used. T0TNFSR treatment resulted in a statistically significant reduction in mechanical allodynia that was apparent 5 days post inoculation compared with the control vector (F (1, 12) ¼ 22.407, Po0.001, SPSS software; Figure 4 ). The anti-allodynic effect of T0TNFSR peaked 2 weeks post inoculation of the HSV vectors. We have shown that inoculation with either T0TNFSR or T0Z subcutaneously in the hind feet of uninjured rats result in no change in mechanical threshold over the course of a few weeks indicating that expression of p55TNFSR does not alter sensory function in normal rats. 33 Expression of p55TNFSR mediated by the T0TNFSR vectors in vivo We have previously reported that the non-replicating HSV vector T0TNFSR produces p55TNFSR in primary DRG neurons in vitro 35 and in the lumbar DRG in vivo following subcutaneous inoculation with the vectors in the hindpaws of rats 35 and that transgenemediated TNFSR is transported to the terminals of primary afferents in the spinal cord. 34, 35 In this study, rats received the inoculation with the vectors T0TNFSR or T0Z (control vectors) in the hindpaws of rats with the gp120-induced neuropathic pain state. On the basis of the behavior effect of T0TNFSR, the ipsilateral L4/5 DRGs and the spinal cords were harvested 2 weeks post inoculation with the vectors and western blots were carried out for the expression of TNFSR in the pooled L4/5 DRG or the spinal dorsal horn. We found that inoculation of T0TNFSR significantly upregulated the expression of TNFSR in the L4/5 DRG (Po0.05 vs T0Z; Figure 5a ) and the spinal dorsal horn (Po0.05 vs T0Z; Figure 5b ).
The anti-allodynic effect of intrathecal CXCR4 antagonist on neuropathic pain induced by gp120 Previous studies have shown that the intradermal administration of SDF1a reduced the mechanical threshold. 40 Sciatic chronic Figure 1 . The expression of TNFa, CXCR4 and SDF1a in the DRG from rats with neuropathic pain induced by gp120 at 2 weeks. Rats received the application of gp120 onto the left sciatic nerve for 2 weeks. Then the ipsilateral L4/5 DRG was harvested. The expression of TNFa, CXCR4 and SDF-1a in the pooled DRG was tested using western blots. Peripheral gp120 induced upregulation of TNFa (a), CXCR4 (b) and SDF-1a (c), *Po0.05 vs sham, **Po0.01 vs sham, t-test, n ¼ 3-4.
constriction injury induces alterations of SDF1 and CXCR4 proteins in the L4/L5 DRG, 41 however, systemic administration of CXCR4 antagonist, AMD3100, reverses thermal hyperalgesia, but not mechanical allodynia. 41 Here, we tested the effect of intrathecal administration of AMD3100 on the gp120 application. For intrathecal administration of AMD3100, intrathecal catheters were implanted under isoflurane anesthesia 42, 43 (see the detailed description in Materials and methods section). Seven days post intrathecal catheters implantation, rats received the gp120 application or the sham surgery. Intrathecal AMD3100 (5 mg in 10 ml) or saline 10 ml was injected (blindly to observer) 2 weeks post gp120 application. Mechanical threshold was measured using Von Frey fibers 30 min before, and 30, 60, 90 and 120 min after intrathecal injection. In the gp120-induced neuropathic pain model, we found that intrathecal AMD3100 (5 mg) significantly reversed mechanical allodynia compared with rats with gp120 þ saline group, Po0.05, two-way ANOVA (SPSS software; Figure 6 ).
The effect of the HSV vector-expressing p55TNFSR on TNFa in the DRG and the spinal cord In this study, we examined whether overexpression of TNFSR mediated by the HSV vectors reduced TNFa in the DRG and the spinal dorsal horn in rats exposed to gp120. Rats received the gp120 application or the sham surgery. One week after surgery, rats with gp120 received either T0TNFSR or T0Z inoculation. In the sham group, animals received T0Z inoculation. The ipsilateral L4/5 DRG and the spinal cords were harvested 2 weeks post inoculation of the HSV vectors and western blots were carried out to assess the expression of TNFa in the pooled L4/5 DRG or the spinal dorsal horn. Neuropathic rats inoculated with T0Z showed a statistically significant increase in TNFa in the DRG (Po0.01 vs sham þ T0Z, one-way ANOVA; Figure 7a ) and the spinal cord (Po0.05 vs sham þ T0Z, one-way ANOVA; Figure 7b ) compared with the sham rats. TNFa expression in neuropathic rats with T0TNFSR, was significantly lower than that with T0Z in Figure 2 . The expression of TNFa, CXCR4 and SDF1a in the spinal dorsal horn in neuropathic pain induced by gp120 at 2 weeks. Rats received the application of gp120 into the left sciatic nerve for 2 weeks. Then the ipsilateral spinal dorsal horn was harvested and the expression of TNFa, CXCR4 and SDF-1a in the spinal dorsal horn was tested using western blots. Peripheral gp120 induced upregulation of the spinal TNFa (a), CXCR4 (b) and SDF-1a (c), *Po0.05 vs sham, t-test, n ¼ 3-4. Figure 3 . The expression of TNFa, CXCR4 and SDF1a in the DRG and the spinal dorsal horn in neuropathic pain induced by gp120 at 7 weeks. Rats received the application of gp120 into the left sciatic nerve. At 7 weeks, the ipsilateral L4/5 DRG and the spinal dorsal horn were harvested. The expression of TNFa, CXCR4 and SDF-1a in the pooled DRG and the spinal dorsal horn was tested using western blots. Peripheral gp120 did not significantly change the expression of TNFa, CXCR4 and SDF1a in the L4/5 DRG (a-c) and the spinal dorsal horn (d-f ) compared with the sham, n ¼ 3-4.
the DRG (Po0.01 vs gp120 þ T0Z, one-way ANOVA; Figure 7a ) and the spinal cord (Po0.05 vs gp120 þ T0Z, one-way ANOVA; Figure 7b ).
The effect of the HSV vector-expressing p55TNFSR on CXCR4 and SDF1a in the DRG and the spinal dorsal horn It has been reported that CXCR4 expression is inhibited by TNFa neutralizing antibody in cultured HGC27 cells. 27 However, it is not clear if inhibition of TNFa also reduces production of CXCR4 and/ or SDF1a in vivo in the gp120-induced neuropathic pain state. In this study, we investigated whether overexpression of TNFSR mediated by the HSV vector reduced CXCR4 and SDF1a in the neuropathic pain state. The ipsilateral L4/5 DRG and the spinal cords were harvested 2 weeks post vectors and western blots were carried out for the expression of CXCR4/SDF1a in the pooled L4/5 DRG or the spinal dorsal horn. Neuropathic rats inoculated with T0Z showed a statistically significant increase in CXCR4 compared with the sham group in both the DRG (Po0.01 vs sham þ T0Z, one-way ANOVA; Figure 8a ) and the spinal cord (Po0.05 vs sham þ T0Z, one-way ANOVA; Figure 8b ). The expression of CXCR4 in neuropathic rats treated with T0TNFSR was significantly lower than that in neuropathic rats with T0Z in both the DRG (Po0.01 vs gp120 þ T0Z, one-way ANOVA; Figure 8a ) and the spinal cord (Po0.05 vs gp120 þ T0Z, one-way ANOVA; Figure 8b) . Similarly, neuropathic rats inoculated with T0Z showed a statistically significant increase in SDF1a expression compared with the sham group in both the DRG (Po0.01 vs sham þ T0Z, one-way ANOVA; Figure 9a ) and the spinal cord (Po0.01 vs sham þ T0Z, one-way ANOVA; Figure 9b ). The expression of SDF1a in neuropathic rats with T0TNFSR was significantly lower than that in neuropathic rats with T0Z in the DRG (Po0.01 vs gp120 þ T0Z, one-way ANOVA; Figure 9a ) and the spinal cord (Po0.01 vs gp120 þ T0Z, one-way ANOVA; Figure 9b ). These data suggest that CXCR4 and SDF1a are likely downstream factors of TNFa.
DISCUSSION
These results of this study demonstrated that (1) the application of HIV gp120 onto the sciatic nerve induced upregulation of TNFa, CXCR4 and SDF1a in both the lumbar spinal cord and the L4/5 DRG; (2) the HSV vector-expressing p55TNFSR reversed mechanical allodynia induced by gp120; (3) intrathecal administration of the CXCR4 antagonist, AMD3100, reversed mechanical allodynia; and (4) the HSV vector-expressing p55TNFSR reversed upregulation of TNFa, CXCR4 and SDF1a induced by gp120 in the DRG and the spinal dorsal horn. We conclude that the HSV vectors expressing TNFSR significantly suppressed neuropathic pain through the inhibition of TNFa that in turn reduced CXCR4/SDF1a expression induced by gp120 in the DRG and the spinal dorsal horn.
The HIV gp120-exposed sciatic nerve exhibits notably axonal swelling and increases TNFa within the nerve trunk. 10 Painpositive HIV patients show TNFa overexpression. 8 Nerve injury marker ATF3 is observed in the DRG neurons in the HIV-gp120 model, 13 which reflects the clinical scenario. The presence of macrophages in the nerve is found in the current model 13 correlating well with the clinical scenario. Loss of intraepidermal nerve fibers is known in patients with HIV-distal sensory polyneuropathy and their density is inversely correlated with the presence of HIV-SN in patients. 44 Loss of intraepidermal nerve fiber has been reported in the HIV-gp120 model. 13 In contrast to many neuropathic pain models, the gp120 model developed no hypersensitivity to either heat or cold stimuli. 13 This is consistent with clinical data showing that patients with HIV-related painful neuropathy do not usually present with thermal hypersensitivity. 45 Together, these findings suggest that the peripheral gp120 model, at least in part, represents a relevant approach to the translation from preclinical finding to patients with painful HIV-SN.
In spite of extensive research, the HIV neuropathological mechanisms responsible for the development of this devastating condition remain largely unknown. The entry of HIV into cells requires sequential interaction of gp120 with CD4 glycoprotein and chemokine receptors (CXCR4 and/or CCR5 as co-receptors of gp120) on the cell surface [46] [47] [48] [49] to induce neurological dysfunction. [50] [51] [52] [53] HIV gp120 exerts both direct and indirect neurotoxic effects on the nervous system through the release of proinflammatory factors. 54 The first mechanism of peripheral neuropathy is a direct result of viral proteins, such as gp120, or elements of the HIV viral genome (see reviews, Theroux et al., 1 Kaul et al. 54 and Ghafouri et al. 55 ), defined as 'virotoxins'. 56 Infected macrophages shed these harmful viral proteins, which lead to an activation of apoptotic pathways, disruption of the BBB and increased release of inflammatory cytokines (for example, TNFa). 1 Many neurons and astrocytes also express CXCR4 and CCR5 raising the possibility of direct interaction with gp120. 54 The second mechanism (indirect approach) is related to proinflammatory molecules in the host's own cells including non-infected TNF-soluble receptor reduces HIV gp120-related neuropathic pain W Huang et al cells defined as 'cellular toxins'. 57 The activated macrophages and microglia begin to release inflammatory cytokines (for example, TNFa), chemokines and other neurotoxins 54, 55 to enhance the neuropathy.
The increased levels of TNFa in human CSF, 58-62 blood plasma, 63 brain 62, [64] [65] [66] and spinal cord 8 have been reported in patients with HIV. It is believed that the nerve injury initiates a cascade of events that lead to the development of chronic pain in patients with HIV. 67 Therefore, the early presence of cytokines may be involved in the induction and/or progression of HIV-distal sensory polyneuropathy neuropathic pain. Kitano et al. 68 have reported that the HIV viral production is suppressed in the presence of TNF antibodies. Williams et al. 69 have reported that the interplay of TNFa and HIV-1 leads to enhanced expression of toxic chemokines. Sui et al. 70 have shown that the HIV protein influences neuronal survival by increasing in TNFa production. Intrathecal administration of soluble gp120 induces neuropathic pain and proinflammatory cytokine release in the spinal cord. 71 Along with others, we have reported that the application of the recombinant gp120 to the sciatic nerve increases TNFa in the DRG and the spinal cord. 10, 15 Furthermore, intrathecal TNFa small interfering RNA or TNFSR reduces the gp120 application-induced mechanical allodynia indicating that TNFa in the spinal cord and/ or the DRG are involved in neuropathic pain induced by HIV gp120. 15 In the current studies, we provided further evidence showing the blockage of TNFa using the HSV vectors expressing TNFSR suppresses neuropathic pain induced by gp120.
CXCR4 is an important factor in the neuropathogenesis of HIV/ AIDS. 21 HIV gp120 binds to and activates CXCR4 expressed by the DRG neurons in a CD-4-independent manner 40, 72 suggesting direct neurotoxic effects of gp120 on the neurons. 73 The effect of the drug is dependent on the route of administration, dosage and pain models and so on. Bhangoo et al. 24 have found that mechanical hypersensitivity produced by antiretroviral toxic neuropathy is inhibited by intraperitoneal AMD3100 (IP, 5 mg kg -1 ). Dubovy et al. 41 reported that intraperitoneal AMD3100 (5 mg kg -1 ) does not attenuate mechanical allodynia but reversed thermal hyperalgesia in the chronic constriction injury model. Bhangoo et al. 74 reported that AMD3100 (IP) does not affect gp120-induced mechanical hypernociception but increased the mechanical threshold induced by combination of gp120 and ddC. Wilson et al. 25 showed that AMD3100 (IP) completely reverses morphine-induced tactile hyperalgesia. In our studies, we found that intrathecal AMD3100 (5 mg) inhibited mechanical allodynia induced by the gp120 application. DRGs may be located in the subdural or epidural space and surrounded by a capsule rich in connective tissue. It is possible that intrathecal administration of this agent affect indirectly on the DRGs, however, the detailed mechanisms are not clear. In the future, we will investigate the mechanisms.
Both TNFa and CXCR4 system are involved in the mechanisms of HIV-related neuropathic pain, however, the relationship of TNFa to CXCR4 is not known in chronic pain. The CXCR4 expression is inhibited significantly by TNFa antibody in cultured HGC27 cells. 27 In the current in vivo studies, we found that the blockage of TNFa due to overexpression of TNFSR mediated by the HSV vector reduced CXCR4 and SDF1a in the neuropathic pain state. This suggests that TNFa in neuropathic pain by the gp120 application may at least in part mediate the expression of CXCR4 and SDF1 in the spinal dorsal horn and the DRG. In term of timing, our current data showed that TNFa, CXCR4 and SDF1a were not significantly increased in either the spinal dorsal horn or the DRG at 7 weeks post gp120 exposure (Figure 3) . One limitation of this study is that we do not know if other molecules are involved in the later stages of neuropathic pain in this model. However, it is possible that the observed effects are a 'hit-and-run' tactic where transient increases in these factors that can mediate a long-term pain response or sets off a perpetual cascade of downstream events resulting in chronic pain.
In summary, our results showed that proinflammatory molecules have an important role in the HIV-related neuropathic pain state. Blocking these proinflammatory molecules reduced HIV gp120-induced neuropathic pain. These gene transfer studies provide a novel proof-of-concept approach (gene therapy) to treating HIV-associated neuropathic pain.
MATERIALS AND METHODS

Construction of the HSV vector expressing the p55 TNFSR and delivery
The vector T0TNFSR contains the encoding sequence of human p55TNFSR gene under regulatory control of the HSV ICP0 immediate early promoter in the UL41 locus of an HSV recombinant defective for HSV genes ICP4, Figure 9 . The effect of p55TNFSR mediated by the HSV vectors on the expression of SDF1a in the DRG and the spinal cord. Rats with neuropathic pain were inoculated with T0TNFSR or T0Z 1 week post gp120. In the sham group, rats received T0Z. Two weeks post vectors, the L4/5 DRG and the spinal dorsal horns were harvested. The expression of SDF1a was tested in the pooled L4/5 DRG (a) or the spinal dorsal horns (b) using western blots. The SDF1a expression in rats with gp120 þ T0Z in the DRG or the spinal dorsal horn was upregulated compared with the sham, **Po0.01 vs sham, ANOVA, n ¼ 3-5. The expression of SDF1a in rats with gp120 þ T0TNFSR in the DRG or the spinal dorsal horn was significantly lower than that with gp120 þ T0Z. TNF-soluble receptor reduces HIV gp120-related neuropathic pain W Huang et al ICP22 and ICP27. T0TNFSR was generated as described previously. 33, 35 The control vector T0Z is identical to T0TNFSR except that it contains the Escherichia coli lacZ gene in place of p55 TNFSR. Animals were inoculated subcutaneously in the footpad of the hind paws with 30 ml containing 1 Â 10 9 PFUs with either T0TNFSR or the control vector T0Z 1 weeks after the peripheral gp120 application.
Animals
Male Sprague-Dawley rats weighing 225-250 g were housed one to three per cage approximately 7 days before the beginning of the study. Free access to food and water and maintained on a 12:12 light:dark schedule at 21 1C and 60% humidity. All housing conditions and experimental procedures were approved by the University Animal Care and Use Committee.
Perineural gp120 neuropathic pain model Under anesthesia, the rat's left sciatic nerve was exposed in the popliteal fossa without damaging the nerve construction. A 2 Â 6 mm strip of oxidized regenerated cellulose was previously soaked in 250 ml of a 0.1% rat serum albumin in saline, containing 400 ng of gp120 (Immunodiagnostics, Bedford, MA, USA) or 0.1% rat serum albumin in saline for the sham surgery. A 3-4 mm length of the sciatic nerve was wrapped loosely with the previously soaked cellulose proximal to the trifurcation not to cause any nerve constriction and left in situ. 10, 12 The incision was closed with 4/0 sutures.
Intrathecal catheter implantation
For intrathecal administration of CXCR4 antagonist AMD3100, intrathecal catheters were implanted under isoflurane anesthesia. 42, 43 A polyethylene (PE-10) catheter filled with 0.9% saline was advanced 8 cm caudally through an incision in the atlanto-occipital membrane to position its tip at the level of the lumbar enlargement. The rostral tip of the catheter was passed subcutaneously, externalized on top of the skull and sealed with a stainless-steel plug. Animals (10-15%) showing neurological deficits after implantation were excluded. Animals were used within 5 days after implantation of the catheter.
Mechanical threshold
Animals were placed in transparent plastic cubicles on a mesh floor for an acclimatization period of at least 30 min on the morning of the test day. Mechanical allodynia was determined by assessing paw withdrawal to von Frey hairs of graded tensile strength. A series of calibrated von Frey filaments were presented consecutively to the hind paw in ascending order of strength, with each filament applied for 6 s with sufficient force to cause slight bending against the paw. A positive response was defined as rapid withdrawal and/or licking of the paw immediately upon the application of the stimulus, which was then followed by the application of the next finer von Frey filament. After a negative response, the next higher von Frey filament was applied. Animals that did not respond to a pressure of 15.1 g were assigned to this cutoff value. The tactile stimulus producing a 50% likelihood of withdrawal was determined using the updown method 38, 39 Western blots Under deep anesthesia, the L4-5 DRG or the spinal dorsal horn ipsilateral to the gp120 application was removed rapidly, frozen on dry ice and stored at À 80 1C. These tissues were homogenized in protein lysis buffer (150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing protease inhibitors and phosphatase inhibitors (Phosphatase Inhibitor Cocktails 1/2). The homogenate was centrifuged at 18 000 g for 20 min at 4 1C. The supernatant was collected and assayed for protein concentration using the DC protein assay (Bio-Rad, Hercules, CA, USA). Aliquots containing 30 mg of protein were dissolved in Laemmli buffer and denatured at 95 1C for 5 min; the proteins were separated by 10% Tris-glycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and transferred to a polyvinylidene difluoride membrane. The membranes were blocked with 5% nonfat dry milk in phosphate-buffered saline buffer and then incubated with primary antibodies for overnight at 4 1C, including rabbit polyclonal anti-TNFa (1 : 500, Chemicon, Temecula, CA, USA), goat anti-CXCR4 (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-SDF1a (1:500, ABCAM, Cambridge, MA, USA), goat anti-TNFR1 (1:1000, Santa Cruz Biotechnology) and mouse anti-b-actin (1 : 8000, Sigma, St Louis, MO, USA). The blots were incubated with secondary antibodies (Santa Cruz Biotechnology) and developed in a chemiluminescence solution (Pierce Biotechnology, Rochford, IL, USA). Quantification of western blots was done from the obtained chemiluminescence values (Bio-Rad ChemiDoc, Bio-Rad). Target protein bands were normalized using the amount of b-actin.
Drug and data analysis AMD3100 hydrate (plerixafor, MW 794.5) was purchased from Sigma, dissolved in saline and 10 ml was injected. The statistical significance of the differences of neurochemical changes was determined by the t-test or one-way ANOVA post hoc test following Fisher's protected least significant difference (StatView 5, StatView, Cary, NC, USA). To compare the difference between the time-course curves of the behavioral testing, we used twoway ANOVA with one within-subjects factor (time) and one betweensubjects factor (group) of a general linear model with repeated-measures analysis with IBM SPSS 21 (IBM, Armonk, NY, USA). All data were presented as mean ± s.e.m. and P-values of o0.05 were considered to be statistically significant.
